Chenyue Hang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenyue Hang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Huixun Jia
3 shared publications- Jieqiong Chen
Department of Ophthalmology, Shanghai General Hospital (Shanghai First People’s Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Ting Zhang
From the Department of Ophthalmology (C.H., T.Z., Z.C., T.Z., J.S., T.L., X.W., Y.G., S.Y., H.J., J.C., X.S.), Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University, School of Medicine, Shanghai, China; Shanghai Key Laboratory of Fundus Diseases (C.H., T.Z., Z.C., T.Z., J.S., T.L., X.W., Y.G., S.Y., H.J., J.C., X.S.), Shanghai, China; Shanghai Gene Therapy Center (T.Z., J.S., T.L., X.W., J.C., X.S.), Shanghai, China
3 shared publications Tong Li
3 shared publicationsZhixuan Chen
From the Department of Ophthalmology (C.H., T.Z., Z.C., H.W., L.C., T.Z., Y.J., T.L., J.S., S.Y., Y.G., H.Z., X.J., X.L., H.J., K.Z., X.W., J.C., X.S.), Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China; Shanghai Key Laboratory of Ocular Fundus Diseases (C.H., T.Z., Z.C., H.W., L.C., T.Z., Y.J., T.L., J.S., S.Y., Y.G., H.Z., X.J., X.L., H.J., K.Z., X.W., J.C., X.S.), Shanghai, China
3 shared publicationsJunran Sun
2 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 284, 1-11
Geographic and Phenotypic Variability in RHO-Associated Retinopathy: Evidence From a Chinese Cohort and Global Literature
- 23 December 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 284, 1-11
Open AccessGeographic and Phenotypic Variability in RHO-Associated Retinopathy: Evidence From a Chinese Cohort and Global Literature
- Open Access
- 19 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 282, 253-262
Unveiling Inflammation-Like Retinal Remodeling in CRB1-Associated Inherited Retinal Dystrophies: Insights From a Multicenter Study
- 19 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 282, 253-262
Open AccessUnveiling Inflammation-Like Retinal Remodeling in CRB1-Associated Inherited Retinal Dystrophies: Insights From a Multicenter Study
- Open Access
- 27 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 269-279
Catering to the Era of Gene Therapy: An Objective Staging Strategy for Bietti Crystalline Dystrophy using Principal Component Regression
- 27 May 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 277, 269-279
Open AccessCatering to the Era of Gene Therapy: An Objective Staging Strategy for Bietti Crystalline Dystrophy using Principal Component Regression
- Open Access
- 11 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4684
Long-Term Results of Pediatric Liver Transplantation for Progressive Familial Intrahepatic Cholestasis
We analyzed the long-term survival rate and development of progressive familial intrahepatic cholestasis (PFIC) patients after liver transplantation (LT). From October 2007 to May 2019, 41 patients were diagnosed as PFIC (type I-III) and received LT in Ren Ji Hospital due to end-stage liver diseases. The median age at LT was 2.93 years, with 75.6% of patients receiving living donor liver transplantation (LDLT). The 5- and 10-year patient survival rates after LT were 92.7% and 92.7%, respectively, and no difference was found among the three subtypes of PFIC. Two PFIC type II patients received re-transplantation due to vascular complications. Liver function and bile acid metabolism returned to normal levels in all living recipients. Catch-up growth was recorded as the height and weight Z scores increased from −2.53 and −1.54 to −0.55 and −0.27 with a median follow-up time of 5.55 years. Improved psychomotor ability and age-appropriate study ability was also observed. A total of 72.4% of school-aged recipients exhibited average academic performance. Diarrhea was reported in all PFIC type I recipients but resolved after resin absorptive treatment. However, allograft steatosis occurred in one PFIC type I patient and exhibited a “remission–relapse circle” under the treatment of cholestyramine. In conclusion, LT is an effective treatment for end-stage PFIC patients with encouraging long-term survival rate and development. However, allograft steatosis should be closely monitored in PFIC type I patients even if diarrhea has been well treated.
- 11 August 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (16) , 4684
Open AccessLong-Term Results of Pediatric Liver Transplantation for Progressive Familial Intrahepatic Cholestasis
We analyzed the long-term survival rate and development of progressive familial intrahepatic cholestasis (PFIC) patients after liver transplantation (LT). From October 2007 to May 2019, 41 patients were diagnosed as PFIC (type I-III) and received LT in Ren Ji Hospital due to end-stage liver diseases. The median age at LT was 2.93 years, with 75.6% of patients receiving living donor liver transplantation (LDLT). The 5- and 10-year patient survival rates after LT were 92.7% and 92.7%, respectively, and no difference was found among the three subtypes of PFIC. Two PFIC type II patients received re-transplantation due to vascular complications. Liver function and bile acid metabolism returned to normal levels in all living recipients. Catch-up growth was recorded as the height and weight Z scores increased from −2.53 and −1.54 to −0.55 and −0.27 with a median follow-up time of 5.55 years. Improved psychomotor ability and age-appropriate study ability was also observed. A total of 72.4% of school-aged recipients exhibited average academic performance. Diarrhea was reported in all PFIC type I recipients but resolved after resin absorptive treatment. However, allograft steatosis occurred in one PFIC type I patient and exhibited a “remission–relapse circle” under the treatment of cholestyramine. In conclusion, LT is an effective treatment for end-stage PFIC patients with encouraging long-term survival rate and development. However, allograft steatosis should be closely monitored in PFIC type I patients even if diarrhea has been well treated.